Shortage of Fluoxetine (Medreich) 10 mg capsule

1 Feb 2024

Policy

Fluoxetine (Medreich ®) for the treatment of major depressive disorders and obsessive-compulsive disorder is now listed on the Pharmaceutical Benefits Scheme (PBS) for the current supply shortage under Section 19A.

For more information on Fluoxetine (Medreich ®), please contact the PBS directly.

More news & views

21 November 2024

Upcoming changes to the regulation of stimulant medication in New Zealand

PHARMAC to fund lisdexamfetamine (Vyvanse) and change the regulations for prescribing stimulant medi...

21 November 2024

Valproate prescribing resources

The College has published information regarding prescribing of valproate-containing medicines to ass...

21 November 2024

Member release of report of Mood Disorders Psychodynamic Psychotherapy Evidence Review

The independent review of evidence for long-term psychodynamic psychotherapy for mood disorders is c...